BioCentury | Aug 6, 2012
Company News

Molecular Targeting Technologies, Medical College of Wisconsin deal

...of 99mTc-Duramycin for the non-invasive imaging of dead and dying cells. Molecular Targeting will develop 99mTc-Duramycin...
...in patients with chest pain and plans to start a Phase 0 trial in 2Q13. 99mTc-Duramycin...
Items per page:
1 - 1 of 1